1[1]Greenlee RT,Hill-Harmon MB,Murray T,et al.Cancer statistics.2001.CA Cancer J Clin,2001,51 (1):15-36.
2[2]Bosanquet AG,Bell PB.Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells.J Exp Ther Oncol,2004,4(2):145-154.
3[3]Fruehauf JP,Alberts DS.Assay-assisted treatment selection for women with breast or ovarian cancer.Recent Results Cancer Res,2003,161:126-145.
4[4]Roses AD.How will pharmacogeneties impact the future of research and development?.Drug DiscovToday,2001,6 (2):59-60.
5[5]Konecny G,Crohns C,Pegram M,et al.Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage Ⅲ ovarian cancer.Gynecol Oncol,2000,77 (2):258-263.
6[6]Holloway RW,Mehta RS,Finkler NJ,et al.Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.Gynecol Oncol,2002,87 (1):8-16.
